Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
about
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.Recent advances in "smart" delivery systems for extended drug release in cancer therapy
P2860
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@en
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@en-gb
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@nl
type
label
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@en
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@en-gb
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@nl
prefLabel
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@en
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@en-gb
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@nl
P2093
P2860
P1154
2-s2.0-84978149875
P1433
P1476
Safety and tolerability of eti ...... domized, phase 3 BEACON trial.
@en
P2093
Ahmad Awada
Alison Hannah
Carol Zhao
Chris Twelves
Denise Tomkinson
Edith A Perez
Hope S Rugo
James Buchanan
Joyce O'Shaughnessy
Mary Tagliaferri
P2860
P2888
P356
10.1186/S40064-016-2446-4
P5530
P577
2016-07-08T00:00:00Z
P6179
1053091073